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Antibiotic resistance is one of the most significant challenges to the health care sector in the 21st century.
Amyriad of resistancemechanisms have emerged over the past decades and arewidely disseminatedworld-
wide through bacterial populations. At the same time there have been ever fewer new antibiotics brought to
market, and the pharmaceutical industry increasingly sees antibiotics as a poor investment. Paradoxically,
we are in a Golden Age of understanding how antibiotics work andwhere resistance comes from. This knowl-
edge is fueling a renaissance of interest and innovation in antibiotic discovery, synthesis, and mechanism
that is poised to inform drug discovery to address pressing clinical needs.A Critical Need for New Antibiotics
The Infectious Diseases Society of America, representing the
infectious disease specialists, who are in the front line of anti-
biotic use, has called for the delivery of ten new antibiotic drugs
by the year 2020 (Infectious Diseases Society of America, 2010).
This ‘‘10 x ‘20 initiative’’ is in response to the growing threat of
antibiotic resistant pathogens that are increasingly causes of
death and debilitating disease, not to mention a massive finan-
cial and logistical burden on health care sectors across the globe
(Choffnes et al., 2010). Once confined to health care institutions,
antibiotic resistant pathogens are now frequently found in the
community, making containment and treatment highly chal-
lenging. Drug resistance in the so-called ESKAPE pathogens
(Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aerugi-
nosa, and Enterobacter species) has been highlighted as espe-
cially concerning (Boucher et al., 2009), but to this list we can
add foodborne diseases caused by, for example, Escherichia
coli and Salmonella (DuPont, 2007), Clostridium difficile (Clem-
ents et al., 2010), Mycobacterium tuberculosis (Cegielski,
2010), and increasingly Neisseria gonorrhea (Allen et al., 2011).
This is a problem that is increasing in scope, with new concerns
emerging regularly.
Multidrug resistance (MDR) in these pathogens is now the
norm. Pathogenic strains are accumulating large numbers of
resistance elements, greatly limiting therapeutic options. The
genome of an epidemic MDR strain of A. baumannii revealed
a large 86 kb resistance island that included 45 genes able to
confer resistance to a broad spectrum of antibiotics (Fournier
et al., 2006). The recent outbreak of hemolytic uremic syndrome
in Europe in 2011 caused by E. coli O104:H4 is also instructive
(Bielaszewska et al., 2011). The reference strain had been previ-
ously identified as a rare b-lactam antibiotic sensitive isolate in
2001; when it re-emerged in a 2011 outbreak, it had acquired
a plasmid conferring resistance to a broad spectrum of b-lactam
antibiotics (so-called ESBL phenotype). Sequencing of the
genome of this strain identified a 90 kb plasmid that includes
the extended spectrum b-lactamase CTX-M15, as well as the
TEM-1 b-lactamase (Mellmann et al., 2011). In order to avoid
induction of virulence toxins, antibiotics are not generally used
to treat enterohemorrhagic E. coli infection, nevertheless thisChemistry & Bioexample demonstrates the ability of strains to rapidly acquire
resistance genes and is a testimony to their movement through
bacterial populations by horizontal gene transfer. Similarly, the
recent, highly publicized emergence of isolates of Enterobacter-
iaceae harboring the NDM carbapenemases were resistant to all
available antibiotics, with the exception of colistin, a polycationic
peptide associated with significant human toxicity (Kumarasamy
et al., 2010). Resistance is pervasive and only increasing in
scope and impact.
It is increasingly evident that the origin of the resistance
elements circulating in pathogens is the vast collection of non-
infectious microbes that populate the globe, the antibiotic re-
sistome (Wright, 2007). Antibiotic resistance genes have been
identified in bacteria from soil (D’Costa et al., 2006), water
(Zhang et al., 2009), the deep-subsurface (Brown and Balkwill,
2009) and the deep ocean (Toth et al., 2010). Some of the wide
distribution of resistance genes in environmental organisms
may be the result of human activity, for example, high-level re-
sistance is found in microbes downstream from antibiotic
production plants (Li et al., 2009, 2010); however, the majority
of resistance in the environment is naturally occurring (Allen
et al., 2010). This is supported by the discovery of a plethora of
resistance genes in permafrost dating from the Pleistocene era
30,000 years ago (D’Costa et al., 2011). These findings contrast
with the resistance profiles of pathogens that pre-date the
antibiotic era or have been collected from antibiotic naive popu-
lations, in which resistance is relatively rare but in which gene-
mobilizing elements, such as R-plasmids, are common and
poised to integrate and disseminate resistance genes in the
face of appropriate selection pressure (Davis and Anandan,
1970; Hughes and Datta, 1983; Thaller et al., 2010).
Human use of antibiotics has provided the selective pressure
for capture of resistance elements existing in the environment for
millennia by pathogens. This holds true not only for natural
product antibiotics but also for drugs of completely synthetic
origin, as evidenced by the emergence of horizontally transferred
resistance to the fluoroquinolone antibiotics, such as cipro-
floxacin (Strahilevitz et al., 2009). Here the qnr genes, likely orig-
inating in waterborne bacteria of the Shewanella genus (Poirel
et al., 2005), have been captured on plasmids that are now
widely circulating in Enterobacteriaceae. The rapid emergencelogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 3
Table 1. Recent Innovation in Antibiotics
Class Target Compound Type
Approved antibiotics
Linezolid Oxazolidinone Ribosome Synthetic
Daptomycin Lipopeptide Cell Membrane Natural product
Retapamulin Pleuromutilin Ribosome Semisynthetic
Tigecycline Tetracycline Ribosome Semisynthetic
Fidaxomicin Macrolide RNA
polymerase
Natural Product
Telavancin Glycopeptide Peptidoglycan Semisynthetic
Antibiotics in clinical trials
Omadacycline Tetracycline Ribosome Semisynthetic
ACHN-490 Aminoglycoside Ribosome Semisynthetic
Cethromycin Macrolide Ribosome Semisynthetic
AN3365 Oxaborole Leu-tRNA
synthase
Synthetic
Partial list, see Butler and Cooper (2011) for a more extensive survey.
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biotic era is a reflection of the vast genetic diversity of microbes
on the planet after 3.5 billion years of evolution and the capacity
tomobilize genes vertically and horizontally through populations.
This is the lens through which we must try to understand and
manage antibiotic discovery and resistance in the future.
New Antibiotics: Successes and Challenges
In the face of growing drug resistance in pathogens, new antibi-
otics are required. Over the past decade several antibiotics have
been brought to market (see ref. Butler and Cooper, 2011;
Table 1). However, the vast majority represent relatively minor
alterations to well-known chemical scaffolds, in particular the
b-lactams and fluoroquinolones. Whereas these classes have
been deep wells from which to draw new drugs over the past
decades, wemay be reaching the limits of their safe and effective
chemical diversity. It is sobering to realize that only four of these
new drugs represent chemical scaffolds new to human use:
linezolid, which is a completely synthetic drug, and the natural
products daptomycin, a lipopeptide; fidaxomicin, a macrocyclic
polyketide; and the diterpene pleuromutilin, retapamulin (Fig-
ure 1). None of these four represent truly novel classes of drugs
though having been discovered in decades past and either
repurposed for human use or resurrected from failed discovery
campaigns.
Nevertheless, they all represent important successes in inno-
vative re-visiting of antimicrobial chemical matter with fresh eyes
with resulting clinical benefit. The oxazolidinone scaffold of line-
zolid was first explored by DuPont in the 1980s to treat plant
disease but was eventually elaborated by researchers, first at
Pharmacia, then at Pfizer, by classical medicinal chemistry
efforts guided by biological activity with attention to pharma-
cology into the first-in-class drug Zyvox that was FDA-approved
in 2000 (Barbachyn and Ford, 2003). Similarly, daptomycin was
first explored and then abandoned by Eli Lilly in the 1980s
because of toxicological concerns; it was then acquired in the
mid-1990s by Cubist, re-deployed with alternate dosing, and
received FDA approval in 2003 (Baltz et al., 2005). The pleuromu-4 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rigtilins were discovered 60 years ago and used for over 30 years in
veterinary medicine but revisited by GlaxoSmithKline in the form
of the semisynthetic retapamulin for topical human use, gaining
FDA approval in 2007 (Novak and Shlaes, 2010). Fidaxomicin
has a similar history, separately identified by groups at Lepetit
in 1975 and then at Abbott again in the mid-1980s from actino-
mycetes as a poorly absorbed antibiotic. It was eventually
brought to market in 2011 by Optimer, who took advantage of
the poor solubility to selectively target infections caused by the
serious intestinal pathogen C. difficile, which is responsible for
a number of recent outbreaks of nosocomial disease (Hardesty
and Juang, 2011).
Despite these great examples of the value of revisiting the deep
antimicrobial catalogs of drug companies, none of these antibi-
otics are panaceas to the broader challenge of resistance. Indeed
all of these drugs have limited antimicrobial activity: all are
confined to Gram positive pathogens, retapamulin is available
for topical use only, and fidaxomicin is narrowly focused on
C. difficile. The only new antibiotic with significant utility to treat
infectionscausedbyGramnegativepathogens, agrowingclinical
problem approaching crisis levels (Arias andMurray, 2009; Peleg
and Hooper, 2010), is the third generation semisynthetic tetracy-
cline, tigecycline. Thisantibioticwasapprovedby theFDA in2005
following years of classical semisynthetic medicinal chemistry
effort by the infectious disease group at Wyeth (Sum, 2006).
The lessons in bringing these antibiotics to market are signifi-
cant and reveal the importance of deep experience in antibiotic
drug discovery in the pharmaceutical industry, as well as
tenacity, serendipity, and the value of ‘‘old’’ scaffolds in bringing
new antibiotics to market. This is especially important as the
track record in using target-based approaches guided by geno-
mics and using libraries of synthetic molecules, often tailored for
oral bioavailability in campaigns for a variety of clinical indica-
tions, has proven ineffective so-far in antibiotic drug discovery
(Gwynn et al., 2010; Payne et al., 2007). Lynn Silver has char-
acterized the result as a ‘‘Discovery Void’’ with no new antibiotic
scaffolds successfully identified since daptomycin in 1987
(Silver, 2011). Indeed, the selection of what constitutes the
‘‘best’’ chemical matter for antibiotic drug discovery is a signifi-
cant challenge that needs to be addressed.
Natural products produced by bacteria have been the most
successful source of antibiotic drug scaffolds over the past
decades. Most of these are from soil-derived members of the
actinomycete class. Fungal natural products include the penicil-
lins and cephalosporins (though these can also be produced by
bacteria) and the pleuromutilins. No plant sourced antibiotics
have been clinically approved and synthetic scaffolds are limited
to the quinolones, sulfonamides, the diaminopyridine trimetho-
prim, and the oxazolidinone linezolid. There has been much
discussion about whether we have picked all the ‘‘low hanging
fruit’’ and if continued investigation of actinomycetes will be prof-
itable in the search for new antibiotics (Baltz, 2008); indeed, the
lack of successful new scaffolds and the repeated rediscovery of
known molecules from this source has been cited as a major
reason for the closing of natural products divisions in many large
pharmaceutical companies. Similarly, the lack of new scaffolds
from synthetic molecules, despite 20 years of screening, has
frustrated target-based approaches for new antibacterial drug
discovery.hts reserved
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Figure 1. New Antibiotics Approved for Human Use over the Past Decade
These represent new scaffolds for medical application.
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PerspectiveDefining good antibacterial targets has been an additional
challenge. Leonard Katz has said that ‘‘A good antibiotic target
is one which there is (or will be) a drug’’ (Katz, 2000). This state-
ment reflects the difference between identifying enzyme inhibi-
tors and antibacterial compounds in vitro, which is relatively
easy, and actually advancing molecules into the clinic and
successfully deploying a new drug, which is very hard. The anti-
biotic scaffolds in current use were discovered using cell-basedChemistry & Bioassays with inhibition of growth as the assay. Subsequent
biochemical identification of the molecular targets of these
antibiotics revealed a remarkably limited number that include
the ribosome, enzymes of peptidoglycan biosynthesis, enzymes
of thymidine synthesis, RNA polymerase, DNA topoisomerases,
and the bacterial membrane. Analysis of microbial genomes
suggests a much larger number of potential targets, even using
the strict criteria of essentiality for cell growth, conservationlogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 5
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Figure 2. Antibiotics in Development
Representative new agents in phase 2- and phase
3-stage clinical trials. NXL-104 is not an antibiotic
per se but an inhibitor of b-lactmases.
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Perspectiveacross most important pathogens, absence of similar targets in
humans, and the ability to bind and be blocked by small mole-
cules. Nevertheless, this apparent richness in targets has failed
to generate any new drugs, despite extensive effort by the phar-
maceutical industry over 20 years.
At the same time, changing regulatory guidelines for new anti-
biotics have vexed the antibiotic drug industry (Choffnes et al.,
2010; Projan, 2003; Projan and Shlaes, 2004). Whereas the
global antibiotics market is substantial (US $42 billion in 2009;
Hamad, 2010), the cost of developing new antibacterial drugs,
in particular the high costs of clinical trials, has also risen and
negatively impacted the return on investment for antibiotics in
particular (Choffnes et al., 2010; Cooper and Shlaes, 2011).
Furthermore, since antibiotics are given for short periods of
time and clinicians are increasingly reluctant to use new agents
to preserve their long-term effectiveness, it is not surprising
that the for-profit pharmaceutical sector sees diminishing re-
turns in antibiotics.
All of these challenges have conspired to dramatically reduce
investment in antibacterial drug discovery. Many large pharma-
ceutical companies have greatly reduced or abandoned antibi-
otic discovery all together. The result is a lack of attention (and
associated innovation) and a growing unmet clinical need.
Where Will the New Antibiotics Come from?
In order to face the challenge of resistance and address the
pressing clinical need for new drugs, many approaches must
be considered. It is evident that new investment will be required6 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reservedand that creative methods to incentivize
both the academic and pharmaceutical
sectors are needed to overcome the
unique economic challenges faced by
drugs whose obsolescence is virtually
guaranteed. There are no irresistible anti-
biotics. Several important strategies from
funding public-private initiatives to ex-
tending patent life of antibiotics have
been proposed, and these efforts are
worthy of serious consideration (e.g.,
refs. Laxminarayan and Powers, 2011;
Spellberg et al., 2011). Even if such policy
changes were enacted immediately, the
scientific challenges of identifying new
antibiotics remain formidable. If we have
picked all the low hanging fruit, where
do we look for new antibiotics?
One obvious strategy is the continued
mining of known scaffolds. Elaboration
of bioactive synthetic scaffolds, such as
the oxazolidinones and diaminopyrimi-
dines, have resulted in new compounds
in late-stage clinical trials, and eight qui-
nolone and fluroquinolone derivatives
have come to market since 2000 (Butler and Cooper, 2011).
Similarly, several b-lactams have been introduced to the clinic
in the last decade or are in clinical trials. Semisynthetic modifica-
tion of natural products remains a highly viable approach. Tela-
vancin, the first semisynthetic glycopeptide antibiotic approved
for clinical use was launched in 2009 (Corey et al., 2009), and at
least two additional glycopeptides, oritavancin and dalbavancin,
are in late-stage trials. Other new semisynthetic agents in clinical
trials include the tetracycline omadacycline (PTK-796; Nat. Rev.
Drug Discov., 2009), the aminoglycoside ACHN-490 (Endimiani
et al., 2009), and the ketolide cethromycin (Rafie et al., 2010;
Figure 2). All of these have broad spectrum antimicrobial activity,
including against Gram negative pathogens, which are an
increasingly urgent clinical need. Tellingly, all of these are being
pursued not by big pharma but by small- and medium-sized
pharmaceutical firms.
We certainly have not exhausted the potential for exploiting the
natural chemical diversity of known antibiotic scaffolds. Our
understanding of the molecular mechanisms underlying natural
product biosynthesis, in particular of polyketide and nonriboso-
mal peptide synthetase assembly lines, has greatly matured
over the past decade (Walsh and Fischbach, 2010). The simulta-
neous growth of synthetic biology techniques and reagents, in
particular the plummeting cost of DNA synthesis, has moved
the in vivo manipulation of chemical scaffolds into cost-effective
reality (Keasling, 2010). The heroic pioneering work on the heter-
ologous overexpression (Pfeifer et al., 2002) and engineering
(McDaniel et al., 1999) of the 6-deoxyerythronolide B macrolide
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sible by genetic manipulation of biosynthetic pathways and the
accessibility to gram quantities of chemically complex com-
pounds through fermentation. Antibiotics, their scaffolds or frag-
ments thereof, that otherwise would be too challenging or costly
to access on an industrial scale using total synthesis can be now
conceivably accessed using engineered heterologous hosts. By
modifying antibiotic scaffolds combinatorially using biosynthetic
modifying enzymes and semisynthesis, antimicrobial chemical
space can be increased significantly. Furthermore, chemical
expansion can be performed directly on nonpurified natural pro-
duct extracts followed by activity-guided purification, a process
that has the potential to further expand chemical space (Lo´pez
et al., 2007; Ramallo et al., 2011).
Revisiting abandoned scaffolds is a proven route to new anti-
biotics as evidenced by the histories of linezolid, daptomycin,
retapamulin, and fidaxomicin. Berdy has estimated that by the
year 2,000 approximately 20,000 naturally derived antibiotics
were already known (Be´rdy, 2005). This is a remarkably rich
vein to mine for new leads in clinically useful antibiotics. Most
of these are surely unsuitable for direct entry into clinical use;
however, they do represent largely untapped chemical matter
that, if revisited using a combination of synthetic biology and
semisynthesis, could be a source of a number of new antibiotics.
Furthermore, even if these do not lead to drugs themselves, they
can be very useful in identifying new targets, which can then be
pursued using target-based approaches.
Another route is to seek completely novel compounds. There
are an estimated 200,000 to 250,000 bioactive natural products
([Be´rdy, 2005]; though this number is based on the rate of purifi-
cation and characterization of compounds in the literature, and
the number may be significantly higher). Even if only a small frac-
tion of these have antibiotic activity, this represents a stunning
region of untapped chemical space to explore. Synthetic chem-
icals also represent apotential valuable sourceof newantibiotics.
Here efforts to understand what constitutes suitable chemical
matter, which can penetrate and be retained by bacterial cells,
in particular the difficult Gram negative pathogens with their lipo-
polysaccharide outermembrane and panoply of efflux pumps, is
needed. There are no simple guidelines akin to Lipinski’s ‘‘Rule of
5’’ to guide drug discovers in this area, though some efforts have
beenmade to quantify the physical chemical properties of antibi-
otics (O’Shea and Moser, 2008). The results of these analyses
have been to underline that antibacterial agents occupy unique
chemical space apart from drugs directed to human targets
and that this information needs to inform library preparation for
antibacterial screens. One notable success currently in phase II
trials for treatment of infections caused by Gram negative patho-
gens is the novel oxaborole compound AN3365 (GSK2251052)
fromAnacor (Figure 2; http://www.anacor.com/). This compound
emerged from an antifungal lead that blocked Leu-tRNA synthe-
tase function. The compound is a slow-tight-biding inhibitor of
the enzyme that forms an adduct between the boron atom with
the geminal cis-2030-dihydroxy groups of the ribose from the
terminal adenine nucleotide of the tRNA, thereby trapping the
enzyme-tRNA complex in a form that is incapable of catalysis
(Rock et al., 2007). This scaffold offers the first promising new
class of synthetic anti-Gram negative drug leads since the intro-
duction of fluoroquinolones over 40 years ago.Chemistry & BioAnother route to expand chemical space applies the knowl-
edge rising from systems biology studies over the past decade.
Here the emerging view of the cell is not one comprised of the
linear pathways familiar to biochemistry textbooks but rather
as a complex web of genetic interactions, rife with redundancy
and populated by a collection of key nodes that link cellular
networks (Costanzo et al., 2010). The result is that most genes
(>80%) in an organism are dispensable, that is, they can be
deleted or otherwise inactivated under common laboratory
settings. Thesewould typically be regarded as poor drug targets,
though they may be very ‘‘druggable’’, that is, potently inhibited
by small drug-like molecules. However, in a genetic background
in which such nonessential genes have been deleted, the
number of ‘‘essential’’ genes increases substantially (Sharom
et al., 2004). The importance of these so-called synthetic lethal
interactions to antibiotic discovery is evidenced by the dramatic
increased sensitivity to antibiotics in bacterial strains in which
nonessential genes have been inactivated (Alvarez-Ortega
et al., 2010; Breidenstein et al., 2008; Liu et al., 2010; Tamae
et al., 2008). These genes (the intrinsic resistome; Fajardo et al.,
2008) therefore offer an orthogonal set of molecular targets for
compounds that can enhance antibiotic activity: antibiotic adju-
vants (Kalan andWright, 2011). Target-based discovery of inhib-
itors of the products of these genes are predicted to discover
molecules that potentiate antibiotic action. This approach could
breathe new life into old antibiotics and discarded scaffolds. It
is worth also noting that the majority of members of our current
antibiotic arsenal either block multiple targets, for example,
the b-lactams that covalently inhibit a collection of cell-wall
metabolism enzymes, the fluoroquinolones that block multiple
type II topoisomerases, (in particular, DNA gyrase and topo IV),
or target large macromolecular machines (ribosomes) or struc-
tures (membranes) with pleiotropic downstream effects.
Such combination drugs would be familiar to infectious
disease clinicians as current anti-infective therapy makes ex-
tensive use of combinations, including the antibacterials trime-
thoprim+sulfamethoxazole (Bactrim), quinupristin+ dalfopristin
(Synercid), and the co-formulations of anti-HIV antivirals. The
use of combinations is also well established to decrease the
emergence of resistance and increase efficacy in tuberculosis
treatment and during antifungal therapy. Therefore, multicompo-
nent therapy in the form of antibiotic adjuvants offers a powerful
approach to extend the life of current antibiotics and decrease
the impact of resistance.
We recently reported the successful outcomes of screens to
identify such antibiotic adjuvants in both bacteria (Ejim et al.,
2011) and yeast (Spitzer et al., 2011). In this work, we explored
combinations of known antimicrobials (minocycline for bacteria,
fluconazole for yeast) with off patent non-antimicrobial drugs.
We reasoned that these compounds offer a privileged source
of bioactive compound space; though not themselves antibi-
otics, they may have cryptic activity towards the intrinsic resis-
tome and synergize with antibiotics at sub-MIC concentrations.
This work identified a number of candidate molecules that
synergized with known antibiotics. One pair, minocycline + the
m-opioid receptor agonist loperamide (Immodium), a well know
drug used to treat diarrhea, demonstrated broad activity versus
Gram negative pathogens and was active in a mouse model of
salmonellosis. In yeast, the fungistatic drug fluconazole waslogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 7
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the antidepressant sertraline (Zoloft), and here the combination
was fungicidal and active in an insect model of fungal infection.
Importantly, in many cases, genus and even species specificity
was observed formany combinations. This offers the opportunity
to use the combinations stratagem to direct therapy to specific
pathogens, thereby sparing the larger microbiome and perhaps
reducing opportunity for complications, such as antibiotic-asso-
ciated colitis, often linked to infection by virulent C. difficile.
These studies demonstrate the power of multicomponent
versus single molecular therapy. By combining bioactive com-
pounds, the cellular network can be impacted at multiple sites,
thereby dramatically increasing effective antimicrobial chemical
space and enhancing potency. Given the fact that cryptic antimi-
crobial activity may be revealed using combinations, one need
not be restricted to combining antibiotics with nonantibiotics
as described in these examples. A matrix of a thousand com-
pounds systematically assayed in pairs gives rise to the equiva-
lent of almost 106 unique combinations, higher order mixtures
(well-precedented, e.g., in tuberculosis, HIV, and cancer thera-
pies) scale accordingly, thereby greatly expanding chemical
space (Spitzer et al., 2011).
The concept of compound combinations can also be applied
to direct blockade of antibiotic resistance. Combinations of
b-lactam antibiotics and inhibitors of Ser b-lactamases have
been clinical and commercial successes for decades (Drawz
and Bonomo, 2010). These inhibitors (clavulanic acid, sulbac-
tam, and tazobactam) are b-lactams themselves that covalent
modify the active site Ser but undergo deacylation very slowly,
effectively inactivating the resistance enzyme on a clinical time-
scale. A new cyclic urea b-lactamase inhibitor, NXL-104 (avibac-
tam), has been advanced to phase 2 clinical trials by Novexel, in
combination with the cephalosporin ceftazidime demonstrating
that there remain opportunities to innovate in this area. Similarly,
inhibitors of efflux pumps have been pursued both in the
academic and pharmaceutical arenas (Lomovskaya and Bos-
tian, 2006; Nikaido and Pages, 2011; Page`s and Amaral, 2009).
A growing understanding of the molecular details of efflux
pump mechanism and structure, in particular the tripartite RND
systems of Gram negative bacteria that are leading source of
MDR, is framing this approach. The challenges are significant,
given the heterogeneity and redundancy of efflux systems in
many serious pathogens, but common molecular mechanisms
suggest that the approach is valid.
Conceptually, any resistance mechanism that requires an
active cellular response can be similarly targeted, thereby rescue
‘‘old’’ antibiotics. The challenge of this approach is the fact that in
most cases of resistance, there are many mechanisms circu-
lating in pathogens, for example, aminoglycoside resistance
can occur by a variety of drug modifications (phosphorylation,
acetylation, and adenylylation), efflux, and target modification
(methylation of rRNA). Identifying a single molecule able to block
all these activities is highly improbable. These challenges could
be mitigated through careful attention to resistance epidemi-
ology to identify prominent modes of resistance perhaps in addi-
tion to the use of molecular diagnostics to match the specificity
of inhibitors of resistance with genes circulating in specific clin-
ical settings. The success of the Ser b-lactamase inhibitors is
instructive here, as these have been very useful drugs, despite8 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rigthe heterogeneity of b-lactam resistance. Specific targets, in
which one or only a few resistance mechanisms dominate in
the clinic, are worthy of such campaigns, including the elements
responsible for resistance to vancomycin, Erm-mediated resis-
tance to macrolides, type B streptogramins and lincosamides,
Ser-based ESBL and metallo b-lactamases, and aminoglyco-
side-modifying enzymes.
Another significant opportunity is targeting the bacterial gene
products and associated physiology responsible for infection.
Such inhibitors of microbial virulence have been touted for
some time as orthogonal approaches to antibiotics (Clatworthy
et al., 2007; Stanley and Hung, 2009); however, they could also
be used in combination with these drugs, likely to great effect.
Such molecules include modulators of quorum sensing, biofilm
formation (or dispersal), type III secretion, virulence gene regula-
tion, etc. By including virulence, the target vista for antibiotics
greatly increases. The effect of these molecules though is often
not readily noticeable in changes in in vitro MIC, a standard that
drives antimicrobial drug discovery. However, high-throughput
methods to screen infection in animal models, such as Caeno-
rhabditis elegans, moves this approach into the realm of possi-
bility for more traditional drug discovery approaches (Moy
et al., 2006; Mylonakis et al., 2007).
Conclusions
The challenges before infectious disease clinicians and the anti-
biotic drug discovery communities are formidable. Faced with
a growing spread of resistance genes in pathogens in both health
care settings and in the community, the ability of drug-resistant
bacteria to be carried across the planet in a matter of hours,
and our absolute need of antibiotics to maintain modern medical
interventions from surgery to cancer chemotherapy, the neces-
sity of a well-stocked arsenal of antibiotics is increasingly critical.
The unfortunate retreat of the pharmaceutical industry from this
area at the same critical juncture, as a result of economic, regu-
latory, and scientific challenges, approaches ‘‘perfect storm’’
characterization.
Yet, there are great reasons to be optimistic. The majority of
well-validated targets for antibiotics have been characterized in
terms of both structure and function. Furthermore, crystal
structures of complexes of these targets with antibiotics,
from the ribosome to RNA polymerase to DNA gyrase, are
known and provide drug-target interaction knowledge that
was unheard of even a decade ago. Sources of new com-
pounds from natural product producing actinomycetes to
metagenomic libraries that encode the genetic diversity of
a myriad of ecological niches can be sequenced in an after-
noon yielding the sequence information underlying biosynthetic
pathways. Leveraging these to produce new molecules has
already been successful (Banik et al., 2010). Furthermore,
combining bioactive compounds can dramatically expand
antimicrobial chemical space. Knowledge of the molecular
mechanism of resistance can also inform new antibiotic design
as elegantly shown by the recent rational synthesis of a
glycopeptide analog designed to overcome vancomycin re-
sistance (Xie et al., 2011). Whereas overcoming the practical
financial and regulatory challenges of the drug discovery
process will not be easy, the scientific brain trust is poised
to deliver.hts reserved
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